Claret Capital Secures €575M for European Tech, Life Sciences Growth
September 10, 2026, 3:34 pm
Location: United Kingdom, England, London
Employees: 51-200
Founded date: 2014
Total raised: $43.07M
Location: United Kingdom, England, London
Employees: 11-50
Founded date: 2017
Total raised: $8.48M
Location: Denmark, Capital Region of Denmark, Copenhagen
Employees: 201-500
Founded date: 2001
Total raised: $40M
Claret Capital Partners has finalized its €575 million Fund IV. This significant growth debt fund targets Europe's burgeoning technology and life sciences sectors. It provides flexible, non-dilutive capital. The firm exceeded its €500 million target. Already, 32% of the fund is deployed across 27+ innovative companies. This move dramatically strengthens European innovation funding. Claret is also expanding its pan-European presence. Demand for growth debt is robust. Selective equity markets drive this need. Fund IV positions Claret as a critical player for scaling European champions.
Claret Capital Partners closed its fourth European Growth Capital Fund. It secured €575 million. This sum exceeded its €500 million target. This landmark achievement includes affiliated discretionary mandates. The fund focuses on growth debt investments. It targets technology, life sciences, and impact-focused companies. These businesses span the entire European continent.
The new fund provides critical capital. It supports companies pursuing international expansion. It fuels strategic acquisitions. It also funds vital product development. Claret offers flexible financing solutions. These options result in lower equity dilution for founders. This approach is highly valued in today's market.
Fund IV is already active. It has deployed 32 percent of its capital. This supports over 27 companies. Noteworthy investments include Billie, a B2B buy-now-pay-later platform. It also backs Cinclus Pharma, a clinical-stage pharmaceutical company. PRODA, a commercial real estate software provider, also benefits. Biotech firm Inventiva and sales intelligence platform Surfe are also portfolio companies. These investments highlight the fund's diverse reach.
Investor confidence drove the successful close. Institutional investors committed significant capital. These included pension funds, insurers, and family offices. Public institutions also participated. Private wealth investors joined through an ELTIF structure. The fund will also leverage discretionary co-investment partnerships. This allows for larger transactions. The firm's managing partners noted the fund exceeded expectations. This reflects strong support from limited partners and co-investors.
Claret's track record is strong. This Fund IV follows a previous €297 million fund. That fund reached its final close in 2022. The firm has deployed over €1.5 billion. This supported more than 210 companies across successive fund vintages. This figure includes recycled capital. Its portfolio boasts impressive exits. Cytora was acquired by Applied Systems. Endomag joined Hologic. Logpoint was acquired by Summa Equity. Lyst became part of ZOZO. Tiqets found a home with Expedia. Abivax also completed a successful Nasdaq IPO. These successes underscore Claret’s expertise.
The market demands flexible capital. Equity markets remain highly selective. Founders seek ways to scale without excessive dilution. This environment fuels the need for non-dilutive financing. Claret’s managing partners anticipate accelerating demand. They believe Fund IV is well-positioned to meet this need at scale. They emphasize supporting founders driving real innovation in Europe. This is a monumental time for business and society.
Claret plans to expand its pan-European presence. Team members are now based in Paris. A presence in Berlin is also planned. This expansion strengthens the firm's reach. It enhances its ability to engage with local ecosystems. It ensures closer ties to European innovation hubs. This strategic growth supports a broader investment strategy.
The firm offers loans ranging from €2 million to €100 million. Each opportunity receives individual assessment. Capital uses are broad. Companies can finance organic growth. They can pursue strategic acquisitions. Funding also supports research and development. Capital expenditure, working capital, and marketing are covered. Geographical expansion also benefits. Companies can extend their cash runway. Claret champions a flexible approach. This allows founders to access funding without immediate equity issuance.
This new fund provides significant capacity. It targets European technology and life sciences ecosystems. The capital helps companies reduce equity dilution. This supports various stages of business expansion. The firm's commitment remains strong. It seeks high-quality opportunities. It actively deploys capital. It seeks entrepreneurs building the next generation of European champions.
Fund IV expands Claret’s platform. It gives greater capacity to support European companies. Demand for flexible debt financing continues to rise. That environment encourages founders to consider non-dilutive alternatives. Claret’s leadership remains committed. They support European entrepreneurs. The firm expects investment activity to continue. Founders consistently seek flexible growth capital. This latest fund provides substantial resources for that next phase. This solidifies Claret's vital role. It empowers European innovation.
Claret Capital Partners closed its fourth European Growth Capital Fund. It secured €575 million. This sum exceeded its €500 million target. This landmark achievement includes affiliated discretionary mandates. The fund focuses on growth debt investments. It targets technology, life sciences, and impact-focused companies. These businesses span the entire European continent.
The new fund provides critical capital. It supports companies pursuing international expansion. It fuels strategic acquisitions. It also funds vital product development. Claret offers flexible financing solutions. These options result in lower equity dilution for founders. This approach is highly valued in today's market.
Fund IV is already active. It has deployed 32 percent of its capital. This supports over 27 companies. Noteworthy investments include Billie, a B2B buy-now-pay-later platform. It also backs Cinclus Pharma, a clinical-stage pharmaceutical company. PRODA, a commercial real estate software provider, also benefits. Biotech firm Inventiva and sales intelligence platform Surfe are also portfolio companies. These investments highlight the fund's diverse reach.
Investor confidence drove the successful close. Institutional investors committed significant capital. These included pension funds, insurers, and family offices. Public institutions also participated. Private wealth investors joined through an ELTIF structure. The fund will also leverage discretionary co-investment partnerships. This allows for larger transactions. The firm's managing partners noted the fund exceeded expectations. This reflects strong support from limited partners and co-investors.
Claret's track record is strong. This Fund IV follows a previous €297 million fund. That fund reached its final close in 2022. The firm has deployed over €1.5 billion. This supported more than 210 companies across successive fund vintages. This figure includes recycled capital. Its portfolio boasts impressive exits. Cytora was acquired by Applied Systems. Endomag joined Hologic. Logpoint was acquired by Summa Equity. Lyst became part of ZOZO. Tiqets found a home with Expedia. Abivax also completed a successful Nasdaq IPO. These successes underscore Claret’s expertise.
The market demands flexible capital. Equity markets remain highly selective. Founders seek ways to scale without excessive dilution. This environment fuels the need for non-dilutive financing. Claret’s managing partners anticipate accelerating demand. They believe Fund IV is well-positioned to meet this need at scale. They emphasize supporting founders driving real innovation in Europe. This is a monumental time for business and society.
Claret plans to expand its pan-European presence. Team members are now based in Paris. A presence in Berlin is also planned. This expansion strengthens the firm's reach. It enhances its ability to engage with local ecosystems. It ensures closer ties to European innovation hubs. This strategic growth supports a broader investment strategy.
The firm offers loans ranging from €2 million to €100 million. Each opportunity receives individual assessment. Capital uses are broad. Companies can finance organic growth. They can pursue strategic acquisitions. Funding also supports research and development. Capital expenditure, working capital, and marketing are covered. Geographical expansion also benefits. Companies can extend their cash runway. Claret champions a flexible approach. This allows founders to access funding without immediate equity issuance.
This new fund provides significant capacity. It targets European technology and life sciences ecosystems. The capital helps companies reduce equity dilution. This supports various stages of business expansion. The firm's commitment remains strong. It seeks high-quality opportunities. It actively deploys capital. It seeks entrepreneurs building the next generation of European champions.
Fund IV expands Claret’s platform. It gives greater capacity to support European companies. Demand for flexible debt financing continues to rise. That environment encourages founders to consider non-dilutive alternatives. Claret’s leadership remains committed. They support European entrepreneurs. The firm expects investment activity to continue. Founders consistently seek flexible growth capital. This latest fund provides substantial resources for that next phase. This solidifies Claret's vital role. It empowers European innovation.